SCHEMBL3901504

SCHEMBL3901504

CN(C)C(C)(C)C(NC(=O)c1c(Cl)cc(Cl)cc1Cl)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.43
ACLY P53396 2/20 0.41
ALDH1A1 P00352 4/20 0.40
GAA P10253 1/20 0.40
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
PTPRC P08575 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GPR139 Q6DWJ6 2/20 0.38
TACR1 P25103 1/20 0.37
HTT P42858 1/20 0.36
PRSS1 P07477 1/20 0.36
CTSG P08311 1/20 0.36
CTRB1 P17538 1/20 0.36
CMA1 P23946 1/20 0.36
THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3902170 0.90 LMNA (0.44) LMNAALDH1A1SMN1; SMN2GPR139HTT
SCHEMBL3905654 0.89 LMNA (0.42) LMNAACLYALDH1A1GAASMN1; SMN2
SCHEMBL3905283 0.85 MEN1 (0.49) ALDH1A1GAAGPR139HTTTHRB
SCHEMBL13663851 0.83 LMNA (0.38) LMNAACLYALDH1A1GAASMN1; SMN2
SCHEMBL3906111 0.82 UTS2R (0.50) LMNAALDH1A1SMN1; SMN2
SCHEMBL3905209 0.82 LMNA (0.36) LMNAALDH1A1GAASMN1; SMN2GPR139
SCHEMBL3901053 0.82 GPR139 (0.49) LMNAALDH1A1SMN1; SMN2GPR139HTT
SCHEMBL3904017 0.81 LMNA (0.40) LMNAALDH1A1SMN1; SMN2HTTPRSS1
SCHEMBL3914045 0.81 LMNA (0.40) LMNAALDH1A1SMN1; SMN2
SCHEMBL13662320 0.81 LMNA (0.43) LMNAALDH1A1SMN1; SMN2HTTPRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1838663-B1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LTD (GB) 2009-01-21 EP claimed
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
EP-1838663-B1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LTD (GB) 2009-01-21 EP disclosed
WO-2006067417-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS SLC18A2, SLC6A5, SLC1A2 LMNA 4455/4885ACLY 1262/4885ALDH1A1 1358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.